Carlos E. Ibañez, Ph.D. is a co-founder of Abintus and serves as our Chief Technology Officer. Dr. Ibañez brings 27+ years of operations experience specializing in the field of viral gene and cell therapies from company start-up and early development through Phase III PPQ validation for commercial manufacturing processes for companies such as Viagene Inc, Chiron Corporation, Oxford BioMedica and Tocagen Inc. Dr. Ibañez is a trusted leader who builds and leads teams that are committed to excellence and continuous learning. His deep understanding of viral vector biology is combined with extensive regulatory experience and an emphasis on designing scalable manufacturing processes that can meet the needs of clinical trials and global commercial supply. Dr. Ibañez is a pioneer in the development of stable viral vector production cell lines adapted to serum free suspension cultures; automated continuous perfusion fed single-use bioreactor systems; downstream chromatography purification of viral vectors; product formulation of viral based therapies for IV administration; and the development of effective lot release and stability testing strategies in concordance with extensive product characterization and comparability testing. Dr. Ibañez has led CMC interactions with FDA and EMA for a viral vector product that achieved Breakthrough Therapy Designation (BTD) and PRIority MEdicines (PRIME) designation, respectively. Dr. Ibañez is an inventor on multiple issued patents related to cell lines and manufacturing. Dr. Ibañez holds a Ph.D. in molecular pathology from the University of California, San Diego and completed a post-doctoral fellowship at the Research Institute at Scripps Clinic.